ABSTRACT
Oxaliplatin is an effective chemotherapeutic agent frequently used in the treatment of colorectal carcinoma. Rare cases of renal failure and hemolytic reactions have been reported as separate side effects of oxaliplatin. Here we present a clinical picture of immune-related intravascular hemolysis and acute tubular necrosis in a patient receiving this drug. This case suggests a mechanistic explanation of renal failure in patients treated with oxaliplatin.
Subject(s)
Acute Kidney Injury/chemically induced , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Hemolysis/drug effects , Acute Kidney Injury/physiopathology , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal, Humanized , Cetuximab , Colonic Neoplasms/drug therapy , Colonic Neoplasms/pathology , Fluorouracil/administration & dosage , Humans , Leucovorin/administration & dosage , Male , Middle Aged , Organoplatinum Compounds/administration & dosage , Oxaliplatin , PrognosisSubject(s)
Antibodies, Monoclonal/adverse effects , Blepharitis/chemically induced , ErbB Receptors/antagonists & inhibitors , Protein Kinase Inhibitors/adverse effects , Antibodies, Monoclonal, Humanized , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cetuximab , Colonic Neoplasms/drug therapy , Female , Humans , Middle AgedSubject(s)
Lung Neoplasms/drug therapy , Lung Neoplasms/secondary , Nasopharyngeal Neoplasms/drug therapy , Nasopharyngeal Neoplasms/pathology , Osteoarthropathy, Primary Hypertrophic/drug therapy , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Remodeling , Female , Humans , Osteoarthropathy, Primary Hypertrophic/etiology , Treatment OutcomeABSTRACT
We report on the characteristics of 21 patients with hepatosplenic gammadelta T-cell lymphoma (HSgammadeltaTCL), an entity recognized since 1994 in the Revised European American Lymphoma (REAL) classification. Median age was 34 years. Patients had splenomegaly (n = 21), hepatomegaly (n = 15), and thrombocytopenia (n = 20). Histopathologic findings were homogeneous and showed the presence of medium-sized lymphoma cells within the sinusoids of splenic red pulp, liver, and bone marrow. Marrow involvement was usually mild but could be demonstrated by phenotyping in all patients. Cells were CD3+CD5-, expressed the gammadelta T-cell receptor, and had a nonactivated cytotoxic cell phenotype (TIA-1+, granzyme B-). Most patients were CD4-/CD8- (16 of 18); CD56+ (15 of 18), expressed the Vdelta1epitope (Vd1+/Vd2-/Vd3-) (9 of 12); and were negative for Epstein-Barr virus (EBV) (18 of 20). Isochromosome arm 7q was documented in 9 of 13 patients. Eight patients had previously undergone kidney transplantation or had a history of systemic lupus, Hodgkin disease, or malaria. Prognosis was poor; median survival time was 16 months, and all but 2 patients ultimately died despite consolidative or salvage high-dose therapy. In conclusion, HSgammadeltaTCL is a disease with distinctive clinical, histopathologic, and phenotypic characteristics. Bone marrow biopsy with combined phenotyping is sufficient for diagnosis, and splenectomy is therefore unwarranted. Current treatment modalities appear to be ineffective in most patients.
